Why Johnson & Johnson's Strong Pharmaceutical Business Is A Concern


27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.


Johnson & Johnson (NYSE: JNJ) came out with better than expected earnings on Tuesday despite the strong headwind it faced from the rising dollar. The company reported first-quarter EPS of $1.56, compared to $1.54 in the same quarter last year, while revenue dropped to $17.4 billion, from $18.1 billion.

 

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Barbara Ryan, Clermont Partners, was on CNBC recently to share her outlook on Johnson & Johnson and the company’s M&A activity.

 

Concerns About Pharma

 


FREE REPORT: How To Learn Options Trading Fast

In this special report, you will learn the four best strategies for trading options, how to stay safe as a complete beginner, ​a 411% trade case study, PLUS how to access two new potential winning options trades starting today.Claim Your Free Report Here.


“JNJ’s performance has been driven largely by a very strong pharmaceutical business,” Ryan said. “People are a little concerned about that going forward, they have obviously competition in Hepatitis C, there’s some concerns around Remicade which is about 15 percent of the company’s business as it relates to some patent disputes as well as biosimilars, but certainly we see companies like Merck and Pfizer in U.S. benefitting from what we are seeing in immuno oncology [...]”

 

M&A Activity

 

On Johnson & Johnson losing its bid for Pharmacyclics, Inc. (NASDAQ: PCYC) to AbbVie Inc (NYSE: ABBV), Ryan said, “I think if you look at JNJ, it’s been a great collaboration for them, right? Enormously successful drug and Abvie sort of stands to gain more because they want to get into that market.”

 

“I think people are looking at JNJ from the perspective that they have $20 billion in cash what are they going to do with that. They sold Cordis…so they have been focussed on getting out of some of the slower growth, lower operating margin portions of their business and will they in fact do more M&A in pharma,” Ryan concluded.


27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.


Posted In: CNBCMedia